FDA label f68a2ea6-e62f-4a7b-8acb-64ebb0b89e37
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- SPL set ID
- 429e9731-cc5d-4089-bf4a-81ec22824c9e
- SPL ID
- f68a2ea6-e62f-4a7b-8acb-64ebb0b89e37
- Version
- 2
- Effective date
- 2016-06-16
- Source export date
- 2026-10-12
- Source partition
- 13
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0013-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-10-12/b8dac220ac9fc8ffb4d86c6e00ece30169fc4575ca0cc92e5c9ce1a524fb0249/drug-label-0013-of-0014.json.zip
- Source manifest SHA-256
- 7e6b178df8f32cac9a78e0f5d09c588344509b04fe41effb1dde9102e2a45be6
- Import run
- 20261013T011858Z
- Imported at
- 2026-10-13 03:04:38
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| spl id | f68a2ea6-e62f-4a7b-8acb-64ebb0b89e37 | id | |
| spl set id | 429e9731-cc5d-4089-bf4a-81ec22824c9e | set_id |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Cardiovascular Thrombotic Events • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (See and ). WARNINGS PRECAUTIONS • Indomethacin Extended-release Capsules are contraindicated in the setting of coronary artery bypass graft (CABG) surgery (See and ). CONTRAINDICATIONS WARNINGS Gastrointestinal Risk • NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (See ). WARNINGS
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings
WARNINGS:
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions table
<table width="595"> <tbody> <tr styleCode="First Last"> <td align="left" valign="top">tinnitus </td> <td align="left" valign="top">ocular-corneal deposits and retinal disturbances, including those of macula, have been reported in some patients on prolonged therapy with indomethacin </td> <td align="left" valign="top"> <paragraph>blurred vision</paragraph> <paragraph>diplopia</paragraph> <paragraph>hearing disturbances, deafness </paragraph> </td> </tr> </tbody> </table>
adverse reactions table
<table width="595"> <tbody> <tr styleCode="First Last"> <td align="left" valign="top">none </td> <td align="left" valign="top"> <paragraph>hypertension</paragraph> <paragraph>hypotension</paragraph> <paragraph>tachycardia</paragraph> <paragraph>chest pain </paragraph> </td> <td align="left" valign="top"> <paragraph>congestive heart failure</paragraph> <paragraph>arrhythmia; palpitations </paragraph> </td> </tr> </tbody> </table>
adverse reactions table
<table width="595"> <tbody> <tr styleCode="First Last"> <td align="left" valign="top">none </td> <td align="left" valign="top"> <paragraph>edema</paragraph> <paragraph>weight gain</paragraph> <paragraph>fluid retention</paragraph> <paragraph>flushing or sweating </paragraph> </td> <td align="left" valign="top"> <paragraph>hyperglycemia</paragraph> <paragraph>glycosuria hyperkalemia </paragraph> </td> </tr> </tbody> </table>
adverse reactions table
<table width="595"> <tbody> <tr styleCode="First Last"> <td align="left" valign="top">none </td> <td align="left" valign="top"> <paragraph>pruritus</paragraph> <paragraph>rash; urticaria</paragraph> <paragraph>petechiae or ecchymosis </paragraph> </td> <td align="left" valign="top"> <paragraph>exfoliative dermatitis</paragraph> <paragraph>erythema nodosum</paragraph> <paragraph>loss of hair</paragraph> <paragraph>Stevens-Johnson syndrome</paragraph> <paragraph>erythema multiforme</paragraph> <paragraph>toxic epidermal necrolysis </paragraph> </td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.